Accelerated Bookbuild Offering
Oncopeptides
Joint BookrunnerKempen & Co acted as Joint Bookrunner in Oncopeptides’ SEK 1.11bn capital increase
Transaction highlights
- Placement of 7,000,000 new shares, representing c. 10% of Oncopeptides’ outstanding share capital, at an offer price of SEK 158 per share generated gross proceeds of SEK 1.11 billion (c. EUR 110m / USD 130m)
- Offer price represents a discount of 4.8% vis-à-vis the closing price prior to transaction announcement on 9 March 2021
- Proceeds will be used to commercially launch PEPAXTO (also known as melflufen) in the US following recent FDA approval, and, subject to EMA approval, commercial launch in Europe
- Furthermore, proceeds will be used for the continued clinical development within multiple myeloma, expansion into new indications and pre-clinical development of new drug candidate based on Oncopeptides’ peptide-drug conjugate platform
- The transaction attracted interest from a large number of domestic as well as international institutional investors and sector specialists, including Artisan Partners, Bain Capital Public Equity, LP and HealthCor Management
- Following our Joint Bookrunner role in May 2020, we are proud to have assisted this repeat client in raising approximately SEK 2.5 billion in less than a year
- In 2021 year to date, Kempen & Co has already executed 8 transactions for European life sciences companies
Company description
Oncopeptides is a pharmaceutical company that develops pharmaceuticals for the treatment of cancer. Its lead product candidate is PEPAXTO (also known as melflufen), a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma, recently got approved by the FDA for commercial use in the US. Oncopeptides is developing a host of different drug candidates across a variety of indications.
Background Kempen & Co Life Sciences & Healthcare
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
- Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
- Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
- Co-Manager in the USD 165 million Nasdaq Initial Public Offering by Pharvaris
- Passive Bookrunner in the USD 518 million US Public Offering by CureVac
- Lead Manager in the USD 120 million US Public Offering by Merus
- Financial Adviser to DCprime in its merger with Immunicum
- Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
- Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
- Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
- Lead Manager in the USD 85.0 million Nasdaq Initial Public Offering by Galecto
- Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
- Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
- Co-Manager in the USD 49.0 million US Public Offering by Centogene
- Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
- Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
- Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
- Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million
- Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
- Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
- Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
- Co-Manager in the USD 862 million Global Offering by argenx
- Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides
Contact
Lees meer over:
Transactions
No transactions found
Accelerated Bookbuild Offering
PIPE & Rights Issue
Rights Issue
Directed Share Issue to
Capital Increase & Spin-out
Global Accelerated Bookbuild Offering
to
Selling shareholder
Public takeover of
Sale of
Block Trade in Molecular Partners Shares
Real Estate Acquisition Financing
Undisclosed
by
Initial Public Offering on Nasdaq
Initial Public Offering on Nasdaq
Initial Public Offering
US Public Offering
Placing
Capital Increase
US Public Offering
Sale to
Portfolio company of
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Mandatory Convertible Bond Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Capital increase
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
on Nasdaq
Initial Public Offering
Accelerated Bookbuild Offering
Initial Public Offering on Nasdaq
Initial Public Offering on Nasdaq
Accelerated Bookbuild Offering
Capital increase
Private Placement
US Public Offering
Initial Public Offering
US Public Offering
Accelerated Bookbuild Offering
Accelerated Bookbuild Offering
Initial Public Offering
Debt financing
US Public Offering
US Public Offering
Green Revolving Credit Facility
Sale to
Combination with
Accelerated Bookbuild Offering
Sale to
Accelerated Bookbuild Offering
Non-listed equity capital raising
Sale of majority stake to
Secondary Sell-Down in Calliditas Therapeutics
Capital increase
Initial Public Offering
Capital Increase
European FinTech
IPO
Accelerated Bookbuild Offering
Private Placement of shares in
Bridge financing
Undisclosed
Initial Public Offering
Rights issue
Accelerated Bookbuild Offering
US Public Offering
Accelerated Bookbuild Offering
Public Offering
Merger with Arya Sciences Acquisition Corp. and subsequent Nasdaq listing
acquisition of
Initial Public Offering
Private Placement
Private Placement
Accelerated Bookbuild Offering
Global Accelerated Bookbuild Offering
Accelerated bookbuild offering
Sale of 456 unit landmark residential project in prime location The Hague
acquired by
public offer for
Sale and capital increase
and
Sale of Dutch residential development to
Global Offering
Accelerated Bookbuild Offering
Public takeover of
Sale of
to
Accelerated Bookbuild Offering
Capital increase
Global offering
US public offering
Rights issue
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Acquisition of
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Increase of stake in
Initial Public Offering
Acquisition of
Acquisition of
Acquisition of
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Fundraise
Accelerated bookbuild offering
Rights issue Public offer by German listed ADLER Real Estate
for Israeli listed
Public offer by German Vonovia
Accelerated bookbuild offering
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by
to consortium of buyers
US public offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Public offer by
for
Public takeover by German Vonovia
For Austrian Conwert
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Management participation advisory in dual-track sale process
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Accelerated bookbuild and private placement
Rights issue